Narrow search
Showing 1 - 10 of 66
Cover Image
Do Productivity Costs Matter?: The Impact of Including Productivity Costs on the Incremental Costs of Interventions Targeted at Depressive Disorders
Krol, Marieke; Papenburg, Joc; Koopmanschap, Marc; … - In: PharmacoEconomics 29 (2011) 7, pp. 601-619
between the level of productivity costs and the type of depressive disorder, the type of treatment and study characteristics … productivity costs, these costs reflected an average of 60% of total costs per treatment arm. The inclusion or exclusion of … regarding work time lost, the values attached to lost work time, the type of depressive disorder, the type of treatment provided …
Persistent link: https://www.econbiz.de/10011005068
Cover Image
Impact of Treatment Success on Health Service Use and Cost in Depression: Longitudinal Database Analysis
Byford, Sarah; Barrett, Barbara; Despiégel, Nicolas … - In: PharmacoEconomics 29 (2011) 2, pp. 157-170
using antidepressants for at least 6 months after antidepressant treatment has ended. Results: Sociodemographic and clinical … later. Conclusions: Successful cessation of antidepressant medication treatment in adults with depression can result in …
Persistent link: https://www.econbiz.de/10011005073
Cover Image
Medical Resource Utilization and Cost of HIV-Related Care in the Highly Active Antiretroviral Therapy Era at a University Clinic in Sweden
Ghatnekar, Ola; Hjortsberg, Catharina; Gisslén, Magnus … - In: PharmacoEconomics 28 (2010) S1, pp. 49-57
university clinic in Sweden. Methods: A patient registry database for HIV treatment at the Department of Infectious Diseases … successful treatment (HIV-RNA <50 copies/mL) increased from 74% to 92% during the period. The mean cost per patient … treatment were not related to antiretroviral treatment. The non-antiretroviral costs were inversely correlated with HIV …
Persistent link: https://www.econbiz.de/10011005075
Cover Image
Unit Costs for Delivery of Antiretroviral Treatment and Prevention of Mother-to-Child Transmission of HIV: A Systematic Review for Low- and Middle-Income Countries
Galárraga, Omar Galrraga; Wirtz, Veronika J.; … - In: PharmacoEconomics 29 (2011) 7, pp. 579-599
As antiretroviral treatment (ART) for HIV/AIDS is scaled up globally, information on per-person costs is critical to … explicitly reported second-line treatment costs. The second cost driver was laboratory cost in LIC and LMIC (14% and 20%), and …
Persistent link: https://www.econbiz.de/10011005080
Cover Image
Value of Information in the Osteoarthritis Setting: Cost Effectiveness of COX-2 Selective Inhibitors, Traditional NSAIDs and Proton Pump Inhibitors
Latimer, Nicholas; Lord, Joanne; Grant, Robert L.; … - In: PharmacoEconomics 29 (2011) 3, pp. 225-237
Background: Recent National Institute for Health and Clinical Excellence (NICE) guidance recommended that when traditional NSAIDs or cyclo-oxygenase (COX)-2 selective inhibitors are used by people with osteoarthritis (OA), they should be prescribed along with a proton pump inhibitor (PPI)....
Persistent link: https://www.econbiz.de/10011005081
Cover Image
Impact of Rapid Methicillin-Resistant Staphylococcus aureus Polymerase Chain Reaction Testing on Mortality and Cost Effectiveness in Hospitalized Patients with Bacteraemia: A Decision Model
Brown, Jack; Paladino, Joseph A. - In: PharmacoEconomics 28 (2010) 7, pp. 567-575
regarding treatment regimens, outcomes and costs was conducted. Information detailing the rates of infection, as well as the …-synthetic penicillin (SSP) for MSSA, 36% for patients receiving empiric vancomycin treatment for MRSA, 59% for patients receiving empiric …
Persistent link: https://www.econbiz.de/10008505441
Cover Image
Cost Effectiveness of Leukotriene Receptor Antagonists versus Long-Acting Beta-2 Agonists as Add-On Therapy to Inhaled Corticosteroids for Asthma: A Pragmatic Trial
Wilson, Edward C.F.; Price, David; Musgrave, Stanley D.; … - In: PharmacoEconomics 28 (2010) 7, pp. 597-608
Background:Background: Information is lacking on the relative effectiveness and cost effectiveness - in a real-life primary-care setting - of leukotriene receptor antagonists (LTRAs) and long-acting β2 adrenergic receptor agonists (β2 agonists) as add-on therapy for patients whose asthma...
Persistent link: https://www.econbiz.de/10008505442
Cover Image
Cost Effectiveness of Leukotriene Receptor Antagonists versus Inhaled Corticosteroids for Initial Asthma Controller Therapy: A Pragmatic Trial
Wilson, Edward C.F.; Sims, Erika J.; Musgrave, Stanley D.; … - In: PharmacoEconomics 28 (2010) 7, pp. 585-595
:Results: Over 2 years, resource use was similar between the two treatment groups, but the cost to society per patient was … drug costs. There was a nonsignificant (imputed, adjusted) difference between treatment groups, favouring ICS, in QALYs …
Persistent link: https://www.econbiz.de/10008505444
Cover Image
The Cost of Relapse for Patients with a Manic/Mixed Episode of Bipolar Disorder in the EMBLEM Study
Hong, Jihyung; Reed, Catherine; Novick, Diego; Haro, … - In: PharmacoEconomics 28 (2010) 7, pp. 555-566
symptoms during an acute episode require intensive treatment, frequently leading to inpatient psychiatric care, which places … treatment of BD following an acute manic or mixed episode over a 21-month follow-up period in routine clinical practice in …
Persistent link: https://www.econbiz.de/10008505445
Cover Image
Q-TWiST Analysis of Patients Receiving Temsirolimus or Interferon Alpha for Treatment of Advanced Renal Cell Carcinoma
Zbrozek, Arthur S.; Hudes, Gary; Levy, Donna; Strahs, Andrew - In: PharmacoEconomics 28 (2010) 7, pp. 577-584
Background and Objective:Background and Objective: For patients with advanced cancers, it is important that treatment … toxicity (TWiST). Health states were quality weighted by patient-reported EQ-5D measures collected while receiving treatment …
Persistent link: https://www.econbiz.de/10008505446